MobbleOpen in Mobble ⇢
Business · Stock markets · published 2026-10-09 · via StockTitan

Retension Pharmaceuticals Sets IPO at $12 Per Share

Image via StockTitan
Image via StockTitan

Retension Pharmaceuticals priced an upsized initial public offering at $12.00 per share, consisting of 3,750,000 common shares. The company expects gross proceeds of $45.0 million before underwriting discounts and other expenses, with underwriters holding a 30-day option for up to 562,500 additional shares. Trading on the Nasdaq Capital Market is expected to begin October 9, 2026, and the company plans to use the funds to complete its RTN-001 Phase 2b trial and prepare for a Phase 3 trial.

Expanded Detail

EXPANDED:

Retension Pharmaceuticals, a clinical-stage biopharmaceutical company, is offering all 3,750,000 shares itself under the Nasdaq ticker RTSN. The IPO is priced at $12.00 per share and is expected to raise $45.0 million in gross proceeds before underwriting discounts and expenses. Underwriters hold a

Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Read the full article at StockTitan →
Related stories
TRexBio Prices IPO at $14 Per Share · Stock markets
IIPR Sets Pricing for $50 Million Preferred Stock Offering · Stock markets
Crescent Energy Prices $1 Billion Common Stock Offering to Fund Devon Asset Purchase · Stock markets
Mynt prices IPO at PHP 6.60, targeting $7bn valuation · Stock markets
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Retension Pharmaceuticals Announces Pricing of Initial Public Offering | RTSN Stock News.” Browse more stories.